Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins

Nutricion Hospitalaria

Volumn 25, Issue 2, 2010, Pages 193-206

  Vaquero, M P ^a   Muniz, F J Sánchez ^b   Redondo, S Jiménez ^b   Oliván, P Prats ^b   Higueras, F J ^b   Bastida, S ^b  

^a INSTITUTO DEL FRÍO CSIC   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Alcohol; Diet drug interactions; Fibre; Grapefruit juice; N 3 fatty acids; Oils; Plant sterols; Statins

Indexed keywords

CITRUS X PARADISI; HELIANTHUS;

FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHYTOSTEROL;

BEVERAGE; BLOOD; FOOD DRUG INTERACTION; GRAPEFRUIT; HUMAN; HYPERLIPIDEMIA; REVIEW;

BEVERAGES; CITRUS PARADISI; FATTY ACIDS; FOOD-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PHYTOSTEROLS;

EID: 77950308128     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2010.25.2.4405     Document Type: Review

References (109)

1. Florez J, Freijanes J. Fármacos hipolipoproteinemiantes. In: Florez J, Armijo JA, Mediavilla A, eds. Control de la obesidad. Farmacología humana, Masson SA, pp. 950-953, Barcelona, 1997.
2. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
3. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425
4. Guía europea para la investigación de interacciones medicamentosas. CPMP/EWP/560/95.1997
5. Lairon D. Dietary fibres: effects on lipid metabolism and mechanisms of action. Review. Eur J Clin Nutr 1996; 50: 125-133
6. Richter WO, Jacobs BG, Schwandt P. Interaction between fibre and lovastatin. Lancet 1991; 338: 706.
7. Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract 2007; 61: 1812-1818
8. Moreyra AE, Alan CW, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 2005; 165: 1161-1166
9. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
10. Moghadasian MH. Clinical pharmacology of 3-hidroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65: 1329-1337
11. Sánchez-Muniz FJ, Varela P, Bastida S, González JM. Enfermedad cardiovascular, hipertensión arterial, dislipemias. In: Carbajal A, Varela P, eds. Cuidados farmacológicos y nutricionales en el paciente de edad avanzada. Fundación General de la Universidad Complutense, pp. 1-47, Madrid,: 2001.
12. Smit JW, Wijnne HJ, Schobben F, Sitsen A, de Bruin TW, Erkelens W. Effects of alcohol comsumption on pharmacocki-netics, efficacy and safety of fluvastatin. Am J Cardiol 1995; 76: 89A-96A.
13. Smit JW, Wijnne HJ, Schobben F, Sitsen A, de Bruin TW, Erkelens W. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Int Med 1995; 122: 678-680
14. Bailey DG, Spencer JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felofipine. Clin Invest Med 1989; 2: 357-362
15. Garvan CK, Lipsky J. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933-942
16. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-478
17. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118-127
18. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56-60.
19. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2003; 57: 448-455
20. Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Pharmacol 2005; 60: 494-497
21. Reamy BV, Stephens MB. The grapefruit-drug interaction debate: role of statins. Am Fam Physician 2007; 76: 190-192
22. Stumpt AL, Mayo T, Blum A. Management of grapefruit-drug interactions. Am Fam Physician 2006; 74: 605-608
23. Rogers JD, Zhao J, Liu L. Grapefruit juice increases felodipine oral availability by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553
24. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000; 68: 384-390
25. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81: 495-502.
26. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H et al. Citrus juices inhibit the function. Drug Metab Dispos2005; 33: 518-523
27. Li P, Callery PS, Gan L-S, Balani SK. Estearase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 2007; 35: 1023-1031
28. Li P, Callery PS, Gan L-S, Balani SK. Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 2007; 35: 1203-1208
29. De Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007; 96: 2808-2817
30. Uesawa Y, Mohri K. The use of heat treatment to eliminate drug interactions due grapefruit juice. Biol Pharm Bull 2006; 29: 2274-2278
31. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33: 518-523
32. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M. Orange juice increased the bioavailability of pravastatin, 3-hydroxi-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci 2006; 78: 2852-2859
33. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdom-yolysis associated with pomegranate juice consumption. Am J Cardiol 2006; 98: 705-706
34. Keys A. Coronary heart disease global picture. Atherosclerosis 1975; 22: 149-192
35. Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res 1985; 26: 194-202.
36. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R et al. The diet and 15 years death rate in the seven countries. Am J Epidemiol 1986; 124: 903-915
37. De Roos NM, Boots ML, Siebelink E, Schouten E, Katan MB. Flow-mediated vasodilation is not impaired when HDL-cholesterol is lowered by substituting carbohydrates for monounsaturated fat. Br J Nutr 2001; 86: 181-188
38. Montoya MT, Porres A, Serrano S, Fruchart JC, Mata P, Gerique JAG, et al. Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity. Am J Clin Nutr 2002; 75: 484-491
39. Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr 1998;128: 444S-448S.
40. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992; 12: 911-919
41. Kris-Etherton PM, Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr 1997; 65 (5 Suppl.):1628S-1644S.
42. Sánchez-Muniz FJ, Bastida S, Gutiérrez-García O, Carbajal A. Olive oil-diet improves the simvastatin effects respect to sunflower oil-diet in men with increased cardiovascular risk. A preliminary study. Nutr Hosp 2009; 24: 333-339
43. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-785
44. Sung M, Kim I, Park M, Whang Y, Lee M. Differential effects of dietary fatty acids on the regulation of CYP2E1 and protein kinase C in human hepatoma HepG2 cells. J Med Food 2004; 7: 197-203.
45. Stupans I, Stretch G, Hayball P. Olive oil phenols inhibit human hepatic microsomal activity. J Nutr 2000; 130: 2367-2370
46. Stupans I, Murray M, Kirlich A, Tuck KL, Hayball PJ. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol 2001; 39: 1119-1124
47. Maggie B, Covington MD. Omega-3 fatty acids. Am Fam Physician 2004; 70: 133-140
48. Gruppo Italiano per lo Studio della Sopravvivenza nell Iinfarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455
49. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
50. Panagiotakos DB, Pitsavos C, Zampelas A, Chrysohoou C, Griffin BA, Stefanadis C et al. Fish consumption and the risk of developing acute coronary syndromes: the CARDIO2000 study. Int J Cardiol 2005; 102: 403-409
51. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort. I. Circulation 2006; 113: 195-202.
52. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978; 2: 117-119
53. Terrano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamaru Y et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331
54. Fox PL, DiCorletto PE. Fish oils inhibit endothelial cell proliferation of platelet-derived growth factor like protein. Science 1988; 241: 453-456
55. Hostmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. BMJ 1988; 297: 180-181
56. Geleinjse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499
57. Zampelas A, Panagiotakos DB, Pitsavos C, Das UN, Chrysohoou C, Skoumas Y et al. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study. Am Coll Cardiol 2005; 46: 120-124
58. Dester M, Den Ruijter, Geza Berecki, Opthof T, Verkerk AO. Pro and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc Res 2007; 73: 316-325
59. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Grayboys T, Bilchik B et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383
60. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345
61. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, for the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An anlysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42: 81-87
62. Kumagai K, Nakashima H, Saku K. The HMG-Co A reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111
63. Liu T, Li G, Korantzopoulos P, Goudevenos JA. Statins and prevention of atrial fibrillation in patients with heart failure. Int J Cardiol 2009;135:e83-e84.
64. Comment on Abi Nasr I, Mansencal N, Dubourg O. Management of atrial fibrillation in heart failure in the elderly. Int J Cardiol 2008; 125: 178-182
65. Duzendorfer S, Rothbucher D, Schatzberger P, Reinisch N, Kähler CM, Wiedermann CJ. Mevalonate-dependent inhibition of transendotelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997; 81: 963-969
66. Alberts AW. HMGCo-A reductase inhibitors-the development. Atherosclerosis Rev 1998; 18: 123-131
67. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
68. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4: 385-391
69. Martin de Santa-Olalla, Sánchez-Muniz FJ, Vaquero MP. N-3 fatty acids in glucose metabolism and insulin sensitivity. Nutr Hosp 2009; 24: 203-217
70. Higueras López FJ. Características dietéticas en pacientes dislipémicos con consumo de estatinas en Toledo. Diploma de Estudios Avanzados. Doctorado en Nutrición. Sánchez-Muniz FJ, advisor. Facultad de Farmacia. Madrid: Universidad Complutense. 2007.
71. Higueras FJ, Sánchez-Muniz FJ. Interacción de pescado vs. carne con estatinas en hipercolesterolémicos. X Congreso de la Sociedad Española de Nutrición (SEN) y 1er Simposio de la Fundación Española de la Nutrición (FEN). 2007, Nov 21-24; Segovia, España.
72. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993; 13: 1755-1762
73. Nordøy A, Bønaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998; 243: 163-170
74. Nordøy A, Bønaa K.H, Sandset P.M, Hansen J, Nilsen H. Effect of w-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 2000; 20: 259-265
75. Nord0y A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 2003; 4: 690-697
76. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544-548
77. Nordøy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 2001; 11: 7-16.
78. McKenney JM, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling D et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006; 46: 785-791
79. Sánchez-Muniz FJ, Canales A, Librelotto J, Nus M. El consumo de fitosteroles ¿un arma de doble filo? Grasas y Aceites 2004; 55: 321-327
80. Vanhanen H, Miettinen TA. Effects of sitostanol esters, dissolved in dietary oil, on serum cholesterol, plant sterols and cholesterol precursors. Circulation 1991; 84: II-601.
81. Miettinen TA, Puska P, Gylling H, Vanhanen HT, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308-1312
82. Amundsen AL, Ose L, Nenseter MS, Ntanios FY. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 2002; 76: 338-344
83. Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of cardiovascular disease. Ann Med 2004; 36: 126-134
84. Sánchez-Muniz FJ, Maki KC, Schaefer EJ, Ordovas JM. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. J Nutr 2009; 139: 13-19
85. Miettinen TA, Strandberg TE, Gylling H, for the Finnish Investigators of the Scandinavian Simvastatin Survival Study Group. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Arterioscler Thromb Vasc Biol 2000; 20: 1340-1346
86. O'Neill FH, Patel DD, Knight BL, Neuwirth CKY, Bourbon M, Soutar AK et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001; 21: 832-837
87. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipopro-tein E polymorphism. Metabolism 1993; 42: 895-901.
88. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-166
89. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 39: 150-154
90. De Knijff P, Stalenhoef AF, Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 83: 89-97.
91. Berglund L, Wiklund O, Eggertsen G, Olofsson SO, Eriksson M, Linden T et al. Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. J Intern Med 1993; 233: 173-178
92. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis 2006; 186: 12-19
93. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987; 80: 578-581
94. Gylling H and Miettinen TA. The effect of plant stanol-and sterol-enriched foods on lipid metabolism, serum lipids, and coronary heart disease. Ann Clin Biochem 2005; 42: 254-263
95. Vanhanen H, Kesäniemi YA, Miettinen TA. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 1992; 41: 588-595
96. Uusitupa MIJ, Miettinen TA, Happonen P, Ebeling T, Turtola H, Voutilainen E et al. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arterioscler Thromb 1992; 12: 807-813
97. Vanhanen H, Miettinen TA. Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolemia. Eur J Clin Pharmacol 1992; 42: 127-130
98. Miettinen TA, Gylling H. Effects of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. Am J Cardiol 2005; 96 (Suppl.): 40D-46D.
99. Thompson GR. Additive effect of plant sterol and stanol esters to statin therapy. Am J Cardiol 2005; 96 (Suppl.): 37D-39D.
100. Vanhanen H. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in paravastatin-treated hypercolesterolaemic patients. Eur J Clin Pharmacol 1994; 47: 169-176
101. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37: 1776-1785
102. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997; 96: 4226-4231
103. Vuori AF, Gylling H, Turtola H, Kontula K, Kentonen P, Miettinen TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolaemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000; 20: 500-506
104. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000; 86: 46-52.
105. Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterolenriched fat spread. Atherosclerosis 2001; 156: 329-337
106. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90: 737-740
107. O'Neill FH, Brynes A, Mandeno R, Rendell N, Taylor G, Seed M et al. Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr Metab Cardiovasc Dis 2004; 14: 133-142
108. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravas-tatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587
109. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109 (Suppl. III): 50-57